medical light News
-
Micro Device offers Low Intensity SW Therapy suitable for Home and Mobile Treatment
An exclusive and limited offer is presently being offered to clinics interested in offering treatment. Demo proposal is for a three month period and incorporates minimum 10 patient treatments, of 10 short sessions in 5 days, and follow-up p/p. Micro is the latest MoreNova model, offering patented Large Area Shockwave Technology for treating medical and cosmetic conditions. A small, light and ...
By DirexGroup
-
Advanced Energy Introduces First Fully Integrated, Intelligent Configurable Capacitor Charger for Aesthetic and Surgical Laser Applications
Advanced Energy Industries, Inc. (Nasdaq: AEIS) - a global leader in highly engineered, precision power conversion, measurement and control solutions - today introduced the Excelsys FC1500, the industry’s first capacitor charger and multiple output power supply. The FC1500 delivers constant charge power and eliminates the need for multiple power supplies in medical laser and Intense Pulsed ...
-
Vitanova Biomedical and LiteCure Medical Lasers Announce Global Strategic Partnership
Vitanova Biomedical, the San Antonio, Texas-based biotechnology company dedicated to improving the lives of cancer patients and the healthcare professionals who care for them, has entered a global strategic partnership with LiteCure Medical Lasers. Vitanova’s light-activated targeted cancer drug offers a cost effective and efficacious cancer therapy with the potential to eliminate unwanted ...
-
Another good news for Deep01! Taiwan`s first AI product obtained marketing approval from Japan`s FDA
DeepCT - Intracranial Hemorrhage (ICH) AI Detection Software - developed by Taiwan's high-profile AI start-up team Deep01 - has obtained the marketing approval of Japan's PMDA, which is the first deep learning software officially licensed by Japan in Taiwan , marking a new milestone in Taiwan's AI medical output. Japan has the world's most aging population, and with advanced medical development, ...
-
Avelas Receives FDA Breakthrough Therapy Designation for Pegloprastide (AVB-620) for Use During Breast Cancer Surgery
SAN DIEGO, CA – Avelas Biosciences, Inc., pioneering the field of intraoperative fluorescent cancer imaging, today announced that the company has received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for pegloprastide (AVB-620) for the intraoperative detection and visualization of positive margins during breast cancer surgery. Pegloprastide is designed ...
-
Avelas Announces Top-Line Data Showing Pegloprastide (AVB-620) Can Significantly Improve Cancer Detection in Real-Time During Breast Cancer Surgery
Use of pegloprastide, a fluorescent cancer marker, during surgery correctly identified cancer in up to 75% of patients who may have otherwise been candidates for a repeat (re-excision) surgery Observed re-excision rate was ~6% in patients whose surgeries included pegloprastide; current re-excision rates are estimated at 20-40% among all patients receiving an initial lumpectomy Each year in the ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you